Brand-name specialty drugs dominate the list of the most expensive medications in the U.S. These treatments address chronic, rare, and complex conditions, and they carry steep price tags for predictable reasons. They require special handling and close oversight from specialists, and manufacturers spread development and production costs across very small patient populations. When a drug is the only approved option for an ultra-rare disease, plan sponsors have little or no rebate leverage to soften the blow.
For benefits advisors and self-funded employers, the takeaway is straightforward. With one in 10 Americans living with a rare disease, the odds of a seven-figure claim reaching your plan keep climbing. Understanding these medications, and where formulary intervention is possible, is essential to sound benefit design.
This year’s ranking reflects annualized average wholesale price (AWP) costs, calculated as wholesale acquisition cost (WAC) multiplied by 1.20. Every figure provided represents a gross list price before rebates. Net plan cost after rebates, group purchasing organization (GPO) pricing, or pharmacy benefits management contracts will be substantially lower. Gene therapies and CAR-T therapies are excluded from this list, so the numbers reflect only medications managed under the pharmacy benefit.
Here are the 10 most expensive drugs in the U.S. under the pharmacy benefit in 2026:
1. Myalept ($1,510,000 – $1,560,000)
Indication: Generalized lipodystrophy
Myalept remains the only treatment approved by the U.S. Food and Drug Administration (FDA) for this rare condition of abnormal fat distribution, which affects an estimated 1 to 5 people per million in the U.S. Patients self-administer the drug once daily by subcutaneous injection, using roughly 18 vials per month. There are no therapeutic alternatives, so plans have zero rebate leverage. Myalept operates under a Risk Evaluation and Mitigation Strategy (REMS) program because of the risk of T-cell lymphoma. Its 2026 AWP-adjusted annualized cost marks a 20%-plus increase from the 2023 benchmark of $1.26 million.
2. Danyelza ($1,390,000 – $1,440,000)
Indication: High-risk neuroblastoma (bone/bone marrow)
Danyelza treats both pediatric and adult patients with its monoclonal antibody, which works by slowing or stopping the growth of cancer cells. Neuroblastoma occurs in roughly 10.2 cases per million children under 15, with nearly 500 new cases reported each year in the U.S. At $24,300 per vial and about 48 vials annually, the 2026 AWP-adjusted cost reflects a 38% to 43% jump from the 2023 benchmark of $1.01 million – one of the sharpest price increases on this list.
3. Zokinvy ($1,300,000 – $1,440,000)
Indication: Hutchinson-Gilford Progeria Syndrome (HGPS)
Zokinvy is the first and only FDA-approved treatment for this ultra-rare genetic condition that causes accelerated aging. HGPS occurs in about 1 in 4 million newborns worldwide, with fewer than 400 patients globally. Most patients die before age 15 from cardiovascular complications. Taken orally four times daily, Zokinvy has extended patient lifespan by an average of 2.5 years. Its 2026 AWP-adjusted cost is up from $1.07 million in 2023.
4. Miplyffa (~$1,300,000)
Indication: Niemann-Pick disease type C (NPC)
Miplyffa is the first U.S.-approved treatment for NPC, an ultra-rare inherited metabolic disorder that leads to progressive neurological deterioration. Approximately 900 U.S. patients are affected. Approved by the FDA in 2024, it is one of the most expensive drug launches in recent history. Patients take it orally three times daily in combination with miglustat. As a new entrant with no prior approved alternative, it gives plans no rebate leverage.
5. Kimmtrak (~$1,170,000
Indication: Metastatic uveal melanoma (HLA-A*2:01 positive))
Kimmtrak is the only approved treatment for this rare and aggressive form of eye cancer. A first-in-class bispecific T-cell engager known as ImmTAC, it’s delivered through weekly IV infusions. In clinical trials, Kimmtrak extended overall survival by roughly six months. At $18,760 per vial administered weekly, the 2026 AWP-adjusted annual cost represents a 20% increase from the 2023 benchmark of $975,520.
6. Demser ($960,000 – $1,200,000)
Indication: Pheochromocytoma (adrenal gland tumor)
Demser manages symptoms by inhibiting catecholamine synthesis. Patients take it orally four times daily, and it may be combined with Dibenzyline, pushing combined annual drug costs past $1 million. Demser is a new entrant to the 2026 top 10, replacing Actimmune, which ranked sixth most expensive in 2023 at $819,000. Notably, Demser’s exclusivity has already expired and a generic, metyrosine, is available. That makes this medication one of the clearest formulary intervention opportunities on the list.
7. Spinraza (~$900,000 Year 1 / ~$450,000/year maintenance)
Indication: Spinal muscular atrophy (SMA)
Spinraza is delivered by intrathecal injection to treat SMA in pediatric and adult patients. SMA affects roughly 10,000 to 15,000 U.S. patients. Treatment requires three to four loading doses followed by maintenance injections every four months, indefinitely. Over a patient’s lifetime, cumulative costs can exceed $10 million. Spinraza competes with Zolgensma, a gene therapy, and Evrysdi, an oral option, but it remains the most established choice for many patients.
8. Folotyn (~$1,010,000)
Indication: Relapsed or refractory peripheral T-cell lymphoma (PTCL)
Folotyn is approved to treat this rare and aggressive blood cancer with an incidence of fewer than 1 case per 100,000 people in the U.S. A healthcare professional administers Folotyn by IV infusion weekly for six of every seven weeks, using about 135 vials per year. The drug received a 3% price increase in 2022 and hasn’t been approved in the European Union due to insufficient evidence of clinical evidence. A generic – pralatrexate – is available at roughly 10% below the brand AWP, offering plans a viable cost-management path.
9. Brineura ($916,000 – $1,020,000)
Indication: CLN2 Batten disease
Brineura is the first FDA-approved treatment for this ultra-rare pediatric neurological disorder affecting fewer than one in 1 million people in the U.S. Roughly 20 children are born with the condition each year. Affected children typically lose the ability to walk and talk by age six and rarely survive past age 12. Brineura is administered once every two weeks by intraventricular infusion through a surgically implanted port. Its 2026 AWP-adjusted cost is up 21%-35% from the 2023 benchmark of $755,898.
10. Blincyto (~$905,000)
Indication: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL)
Blincyto is a first-in-class bispecific T-cell engager (BiTE) approved to treat ALL, the most common childhood cancer. However, Blincyto is reserved for relapsed or refractory cases where standard chemotherapy has failed. Treatment consists of continuous IV infusion over four-week cycles, and patients may receive up to nine cycles. About 168 vials are used annually at $4,492 per vial. Blincyto ranked ninth most expensive in 2023 at $754,720. Its 2026 AWP-adjusted cost has risen roughly 20%.
What This Means for Plan Sponsors
Two patterns stand out in the 2026 list. First, price inflation is relentless. Nearly every returning drug posted a 20%-plus increase over its 2023 benchmark, and Danyelza climbed as much as 43%. Second, the list now includes drugs with generic or lower-cost alternatives, Demser and Folotyn among them. Those cases represent real, actionable savings opportunities for plans that maintain strong clinical oversight and an optimized formulary.
For most drugs on this list, no alternative exists, and rebate leverage is minimal. That reality underscores the value of independent clinical review, high-dollar claim management, and supplemental protection against catastrophic specialty claims. Preparing your clients before one of these prescriptions arrives is far more effective than reacting after the claim hits.
Sources: ICER Launch Price and Access Report, October 2025. Manufacturer WAC disclosures. GoodRx. DelveInsight 2024–25. RGA Specialty Pharma 2024. UpToDate AWP Pricing. AWP figures are WAC × 1.20, gross list price pre-rebate. Net plan cost after rebates, GPO pricing, or PBM contracts will be substantially lower.
Learn more:
3 Warning Signs That You’re Overpaying for Specialty Drugs, June 23, 2026
How to Navigate the Complex Pharmacy Benefits Landscape with Confidence, May 19, 2026
10 Most Expensive Drugs in the U.S.: 2023
